National Institutes of Health

Description

This Funding Opportunity Announcement (FOA) solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases unique to pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition. An X02 pre-application is the first step in the application process for RFA-TR-17-002 and RFA-TR-17-003. X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious and relevant to NIH program priorities will be notified of the opportunity to submit a UG3/UH3 application under this FOA. The initial UG3 award will support the development of rigorous, pre-clinical efficacy studies and clinical trial planning activities. If UG3 pre-clinical milestones are met, the UH3 award may be made to support clinical trials.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster <br/>FBOWebmaster@OD.NIH.GOV <br/>
FBOWebmaster@OD.NIH.GOV